Back

Walden to present initial WAL0921 kidney disease data at Kidney Week

Verifying
  • Walden Biosciences will present two WAL0921 posters at Kidney Week in Denver.
  • WAL0921 reduced circulating suPAR levels and was safe and well tolerated in healthy participants.
  • The late-breaking poster will provide initial data from diabetic kidney disease patients.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.